Basit öğe kaydını göster

dc.contributor.authorTakir, Mumtaz
dc.contributor.authorUnal, Asli Dogruk
dc.contributor.authorKostek, Osman
dc.contributor.authorBayraktar, Nilufer
dc.contributor.authorDemirag, Nilgun Guvener
dc.date.accessioned2019-06-20T07:49:53Z
dc.date.available2019-06-20T07:49:53Z
dc.date.issued2016
dc.identifier.issn0211-6995
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0211699516301126?via%3Dihub
dc.identifier.urihttp://hdl.handle.net/11727/3610
dc.description.abstractObjective: To evaluate renal impairment in type 2 diabetic patients with normoalbuminuria or microalbuminuria by detection of serum cystatin C and serum and urinary TGF-beta levels. Methods: Cross-sectional study conducted at the Department of Endocrinology in Baskent University School of Medicine. Patients with type 2 diabetes mellitus without known overt diabetic nephropathy were included in the study. Recruited patients were stratified into four groups, matched in terms of age, gender, microalbuminuria level and estimated GFR calculated with MDRD. Results: 78 patients were enrolled. They were categorized into four groups depending on their urinary albumin excretion and estimated glomerular filtration rate. Macrovascular complication was found to be higher in patients with microalbuminuria than in other patients (p < 0.01), but there were no differences in terms of other diabetic complications. Serum cystatin C level was significantly higher in normoalbuminuric group one patients, while serum and urinary TGF-beta 1 levels were higher in microalbuminuric group two patients. The serum level of cystatin C was found to negatively correlate with eGFR in group two patients (r = -0.892, p < 0.001). Finally, there was a negative correlation between eGFR and cystatin C in all the patient groups (r = -0.726, p=0.001). Conclusions: Although urinary albumin excretion is recommended for the detection of type two diabetic nephropathy, there is a group of patients with decreased eGFR but without increased urinary albumin excretion, in which serum cystatin C level was indicated to be used as an early biomarker of diabetic nephropathy. (C) 2016 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Nefrologia.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.nefro.2016.06.011en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetic nephropathyen_US
dc.subjectCystatin Cen_US
dc.subjectTGF-beta 1en_US
dc.subjectMicroalbuminuriaen_US
dc.subjectNormoalbuminuriaen_US
dc.titleCystatin-C and TGF-beta levels in patients with diabetic nephropathyen_US
dc.typearticleen_US
dc.relation.journalNEFROLOGIAen_US
dc.identifier.volume36en_US
dc.identifier.issue6en_US
dc.identifier.startpage653en_US
dc.identifier.endpage659en_US
dc.identifier.wos000392046800009en_US
dc.identifier.scopus2-s2.0-85044295308en_US
dc.contributor.pubmedID27745866en_US
dc.contributor.orcID0000-0002-7886-3688en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDY-8758-2018en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster